

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Information							
Given Name (First Name) Anthony		2. Surname (Last Name) BUISSON			3. Date 23-January-2018			
4. Are you the corresponding author?		✓ Yes No						
5. Manuscript Titl 2017-2018 ECCO	e D Annual Disclosure of F	Potential Conflicts	of Interest					
6. Manuscript Ide	ntifying Number (if you kr	now it)						
Section 2								
Section 2.	The Work Under Co	onsideration for	Publication					
any aspect of the statistical analysis Are there any re	submitted work (including	g but not limited to g			commercial, private foundation, design, manuscript preparation,			
Section 3.	Relevant financial	activities outsid	e the submitted	work.				
of compensation clicking the "Add Are there any re	n) with entities as descri	ibed in the instruct port relationships t est?	ions. Use one line fo	or each entit	relationships (regardless of ar y; add as many lines as you ne 6 months prior to publicatio	ed by		
Name of Entity		Grant? Person		Other?	Comments			
Abbvie								
MSD								
Ferring								
Takeda								
Pfizer (Hospira)								
Janssen								
Sanofi-Aventis								
Vifor Pharma								



Name of Entity	Grant? Personal Fees?	Non-Financial Support	Other?	Comments	
Biogen					
Amgen					
Continu A					
Section 4. Intellectual Propert	y Patents & Co	pyrights			
Do you have any patents, whether plann	ed, pending or issue	ed, broadly relevar	nt to the v	work? Yes 🗸 No	
Section 5. Relationships not c	overed above				
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/conditions/cir At the time of manuscript acceptance, journals may ask authors to	n the submitted wo litions/circumstance cumstances that pro urnals will ask autho	rk? es are present (exp esent a potential c ors to confirm and,	lain belo	w): interest sary, update their disclosure statement	ts.
Continue		omation about te	porteure	idionships.	
Section 6. Disclosure Statemen	nt				
Based on the above disclosures, this form below.	ા will automatically લ	generate a disclosi	ure statei	ment, which will appear in the box	
Dr. BUISSON reports personal fees from A Takeda, personal fees from Pfizer (Hospii from Vifor Pharma, personal fees from Bi	ra), personal fees fro	om Janssen, persor	nal fees fr	om Sanofi-Aventis, personal fees	



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.